About 7 results found for searched term "Trastuzumab" (0.145 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6218 | Trastuzumab | EGFR/HER2 |
| Herceptin | ||
| Trastuzumab is a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, MW:145.53 KD. | ||
| M10402 | MC-GGFG-DX8951 | Drug-Linker Conjugates for ADC |
| Trastuzumab Impurity 1 | ||
| MC-GGFG-DX8951 is a drug-linker conjugate for ADC with antitumor activity by using DX8951 (a DNA topoisomerase I inhibitor), linked via the protease cleavable MC-GGFG linker. | ||
| M24679 | Trastuzumab beta | EGFR/HER2 |
| ABP 980; Trastuzumab-anns | ||
| Trastuzumab beta (ABP 980) is a biosimilar to Trastuzumab targeting human epidermal growth factor receptor 2 (HER2). Trastuzumab beta can be used for the research of HER2-positive metastatic breast cancer, early breast cancer (EBC), and metastatic gastric cancer. | ||
| M24768 | Trastuzumab duocarmazine | Drug-Linker Conjugates for ADC |
| Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas. | ||
| M24781 | Timigutuzumab | EGFR/HER2 |
| GEXMab73 GT-MAb7.3-GEX TrastuzuMab-GEX | ||
| Timigutuzumab (GEXMab73) is a humanized monoclonal antibody that targets ErbB2. Timigutuzumab can be used for the research of cancer. | ||
| M24828 | Trastuzumab deruxtecan | Drug-Linker Conjugates for ADC |
| DS-8201; DS-8201a | ||
| Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. | ||
| M40546 | Trastuzumab Emtansine | ADC Linker |
| Trastuzumab Emtansine is a HER2-targeting antibody-drug concatenation (ADC) that can be used in studies related to HER2-positive metastatic breast cancer. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
